Celltrion Highlights Dermatology Portfolio Including 'Omliclo' at EADV 2025

Accelerating Expansion into Dermatology Amid Positive Reception from Medical Professionals

Celltrion announced on the 22nd that it has officially entered the dermatology market by participating in the "2025 European Academy of Dermatology and Venereology (EADV)" held in Paris, France, for four days from the 17th to the 20th of this month.

This year marks the 34th EADV, one of the world’s most prestigious dermatology conferences, with more than 16,000 medical professionals in dermatology and venereology attending annually to share the latest clinical research, therapeutic developments, and academic information.

From the 17th to the 20th (local time), participants are visiting the Celltrion booth at the "2025 European Academy of Dermatology and Venereology (EADV)" held in Paris, France. Celltrion

At this event, Celltrion operated its own booth to showcase its brand competitiveness and hosted a symposium titled "Understanding and Utilizing Biosimilars in Chronic Spontaneous Urticaria." The company presented research results for Omiclo (CT-P39, active ingredient: omalizumab), which was recently launched in Europe as a "first mover."

During the symposium, Professor Martin Metz of the Department of Dermatology at Charit? University Hospital in Germany presented 40 weeks of global phase 3 clinical data and follow-up results for Omiclo. He reported that Omiclo demonstrated comparable outcomes to the control group in all indicators, including efficacy, safety, and quality of life (QoL).

The original drug for Omiclo, Xolair, is used to treat chronic spontaneous urticaria and asthma and recorded approximately 6.4992 trillion KRW (about 4.8 billion USD) in global sales last year. Celltrion previously obtained approval for Omiclo as the first Xolair biosimilar in major markets such as Europe and the United States, securing its position as a first mover and sequentially launching the product in Europe to gain early market share.

Celltrion already holds a stable market share in Europe in the fields of autoimmune disease treatments and anticancer drugs. The company plans to further strengthen its position by pioneering new markets such as dermatology.

In addition, at this year’s conference, Celltrion unveiled the global phase 1 clinical trial results for the Cosentyx (active ingredient: secukinumab) biosimilar CT-P55 for the first time in a poster presentation. The phase 1 trial, conducted in healthy adults, confirmed equivalence between CT-P55 and the original drug in terms of pharmacokinetics (PK), safety, and immunogenicity.

Cosentyx is used to treat autoimmune diseases such as moderate-to-severe plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis, with global sales reaching approximately 8.5974 trillion KRW (about 6.4 billion USD) last year. Celltrion is currently conducting a global phase 3 trial for CT-P55, and the company’s dermatology portfolio is expected to expand further in the future.

Ha Taehoon, Head of Celltrion Europe, stated, "Celltrion is a global leader in the field of antibody biosimilars and has built trust through close cooperation with European healthcare professionals. With the launch of Omiclo, currently the only biosimilar available in the European market for dermatology, we will further strengthen our antibody biosimilar product portfolio in the dermatology field, expand communication with healthcare professionals, and solidify Celltrion’s position in the market."

This content was produced with the assistance of AI translation services.